NEW YORK, June 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rocket-pharmaceuticals-i ...

SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Rocket Pharmaceuticals securities during the specified Class Period, alleging misleading statements regarding the safety and clinical trial protocol of RP-A501 [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between February 27, 2025, and May 26, 2025 [1]. - The lawsuit claims that Rocket Pharmaceuticals provided positive statements while concealing material adverse facts, including the risk of Serious Adverse Events (SAEs) and participant deaths in clinical trials [5]. - The firm amended the trial's protocol without informing shareholders, leading to artificially inflated stock prices [5]. Group 2: Investor Participation - Investors who purchased Rocket Pharmaceuticals securities during the Class Period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - Interested investors can join the class action by submitting a form or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 11, 2025, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing shareholder interests [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trial for RP-A501, which resulted in serious adverse events, including patient death [1][4][5]. Company Overview - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare and devastating diseases [3]. Allegations of the Lawsuit - The lawsuit claims that Rocket Pharmaceuticals provided misleading information regarding the safety and clinical trial protocol of RP-A501 while concealing material adverse facts, including the known risks of serious adverse events [4]. - It is alleged that the company amended the trial protocol to include a new immunomodulatory agent without informing shareholders of this critical update [4]. - Following the announcement of a clinical hold by the FDA due to a serious adverse event resulting in a patient's death, the stock price of Rocket Pharmaceuticals fell significantly [5]. Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone, and is recognized for securing significant monetary relief for investors [7].

SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025. The lawsuit comes after investors saw the price of their shares in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) crash over 60% on May 27, 2025 as a result of the company’s announcement that ...

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants provided overw ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW ...

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly misleading investors regarding the viability and efficacy of its gene therapy product RP-A501, particularly in relation to its Phase 2 clinical trial for Danon disease [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Rocket Pharmaceuticals misrepresented the reliability of information regarding the projected timeline and safety of the RP-A501 trial, leading to a false sense of security among investors [2]. - Following the announcement of a Serious Adverse Event (SAE) involving a patient in the trial, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, reflecting a significant loss in market value [3]. Group 2: Company Background - Rocket Pharmaceuticals is described as a fully integrated, late-stage biotechnology company focused on developing gene therapies for rare and severe diseases, emphasizing its commitment to clear clinical endpoints and direct on-target mechanisms of action [1]. Group 3: Legal Proceedings - Shareholders interested in participating in the class action can contact Robbins LLP, which is leading the litigation on a contingency fee basis, meaning no fees or expenses are required from shareholders [4][5].

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) between February 27, 2025, to May 26, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Rondolph Ho v. Rocket Pharmaceuticals, Inc., et al. (Case No. 3:25-cv-10049) has been commenced in the United States District Court ...

28 May 2025 | 9:26AM EDT Rocket Pharmaceuticals Inc. (RCKT): Clinical Hold on Ph. 2 DD Trial Puts Largest Late-Stage Oppy At Risk; Downgrade to Sell w/ $2 PT On Tuesday (5/27), RCKT announced that the FDA placed a clinical hold on its pivotal Ph. 2 Danon disease (DD) trial. The hold was issued on 5/23 after a patient treated in early May experienced capillary leak syndrome that emerged ~1 week after RP-A501 dosing. Although there were some early signs the condition was beginning to improve, the patient subs ...